After the FDA approved lenalidomide for use in chemotherapy-naive multiple myeloma (MM) patients, the European Commission has followed suit. Revlimid was approved today by EC in MM patients, previously untreated and transplant-ineligible.
Regulators in Europe have followed the example of their counterparts across the Atlantic and expanded approval on Celgene’s big-selling multiple myeloma drug Revlimid to include newly-diagnosed patients.
The European Commission has approved Revlimid (lenalidomide) for adults with previously untreated MM who are not eligible for transplant. It is currently marketed in combination with dexamethasone for patients who have received at least one prior therapy.
Read the complete article at PharmaTimes: http://bit.ly/1zTEsDi
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen